Omeros Corp. (OMER) Bullish View Reiterated a FBR Following Encouraging Phase II Data

October 17, 2016 10:25 AM EDT
Get Alerts OMER Hot Sheet
Price: $9.21 +2.91%

Rating Summary:
    10 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 19 | Down: 19 | New: 13
Trade OMER Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

FBR Capital analyst Thomas Yip reiterated an Outperform rating and $38 price target on Omeros Corp. (NASDAQ: OMER) after the company reported interim data from a Phase II trial of OMS721 for patients with renal dysfunction.

Yip commented, "All patients are to be treated with OMS721 with corticosteroid tapering for 12 weeks. To date, two IgA nephropathy patients showed statistically significant declines in urine albumin-to-creatinine ratios (uACRs) and 24-hour proteinuria reductions versus baseline, suggesting improved renal function. Mean baseline uACR declined from 1264 mg/g to 525 mg/g after 12 weeks of treatment (p = 0.011), while mean proteinuria also declined from 3156 mg/day to 1119 mg/day (p = 0.017), along with daily steroid dose reductions. Improvements in the above measurements were seen in two membranous nephropathy patients (although not statistically significant), while neither of the two treated lupus nephritis patients showed renal improvements. Based on these data, Omeros is pursuing breakthrough therapy designation for OMS721 in IgA nephropathy and is amending the Phase II trial's protocol to evaluate five OMS721-treated IgA nephropathy patients against five placebotreated patients. While we think these results in a small patient dataset will need to be confirmed with additional patients, we think OMS721 could tap into another rare disease (estimated annual incidence of ~2.5 per 100,000)."

For an analyst ratings summary and ratings history on Omeros Corp. click here. For more ratings news on Omeros Corp. click here.

Shares of Omeros Corp. closed at $7.34 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Add Your Comment